Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06182774 |
|
Recruitment Status :
Recruiting
First Posted : December 27, 2023
Last Update Posted : April 12, 2024
|
Sponsor:
Canadian Cancer Trials Group
Collaborators:
Canadian Institutes of Health Research (CIHR)
Myeloma Canada
Information provided by (Responsible Party):
Canadian Cancer Trials Group
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 31, 2032 |
| Estimated Study Completion Date : | July 31, 2032 |